Hernández VA, Arias VR, Miranda VL

Language: Spanish
References: 21
Page: 394-394
PDF size: 134.19 Kb.

ABSTRACT

The antiphospholipid syndrome is a heterogeneous pathology with thrombotic, obstetric and non-thrombotic manifestations, associated with the presence of different antiphospholipid antibodies. Its catastrophic form is rare, in most cases it is related to a triggering factor and it manifests itself with the presence of multiple thrombi that can be lodged in any part of the body and that histologically appear as a thrombotic microangiopathy. This disease must be recognized in a timely manner for the immediate establishment of triple therapy, which decreases its mortality.

REFERENCES

1. Mezhov V, Segan JD, Tran H, Cicuttini FM. Antiphospholipid syndrome: a clinical review. Medical Journal of Australia. 2019 07 04;211(4):184-188. https://doi.org/10.5694/mja2.50262

2. Riva N, Gatt A. Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. EMJ Rheumatol. 2019;6(1):101-11.

3. Vadgama TS, Smith A, Bertolaccini ML. Treatment in thrombotic antiphospholipid syndrome: a review. Lupus. 2019 Sep;28(10):1181-8.https://doi.org/10.1177/0961203319864163

4. Bijilsma J, Hachulla E. EULAR Textbook on Rheumathic Diseases. 3rd ed. London: BMJ Publishing Group Ltd; 2018.

5. Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018 Jan 11; 4:17103. https://doi.org/10.1038/nrdp.2018.5

6. Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Current Opinion in Rheumatology. 2016 05;28(3):218-227. https://doi.org/10.1097/bor.0000000000000269

7. Cervera R, Rodríguez-Pinto I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun. 2018 Aug; 92:1-11. https://doi.org/10.1016/j.jaut.2018.05.007

8. Unlu O, Erkan D. Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease. Annual Review of Medicine. 2017 01 14;68(1):287-296. https://doi.org/10.1146/annurev-med- 042915-102529

9. Limper M, Scirč CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, Tektonidou M, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open. 2018 Oct;4(Suppl 1):e000785. https://doi.org/10.1136/rmdopen-2018-000785

10. Rodríguez-Pinto I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016 Dec;15(12):1120-4. https://doi.org/10.1016/j.autrev.2016.09.010

11. Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017 Apr;10(4):365-74.https://doi.org/10.1080/17474086.2017.1300522

12. Rodríguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):239-49. https://doi.org/10.1016/j.berh.2016.07.004

13. Rodriguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: The current management approach. Best Practice & Research Clinical Rheumatology. 2016 04;30(2):239- 249. https://doi.org/10.1016/j.berh.2016.07.004

14. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018 May 24;378(21):2010-21.https://doi.org/10.1056/NEJMra1705454

15. Firestein GS, Budd R, Gabriel SE McInnes IB, O´Dell JR. Kelley and Firestein´s Textbook of Rheumatology. 10th ed. PA: Elsevier Health Sciences; 2017.

16. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases. 2019 05 15;78(10):1296-1304. https://doi.org/10.1136/annrheumdis-2019-215213

17. Legault K, Schunemann H, Hillis C, Yeung C, Ak EA, Carrier M, et al. McMaster RARE􀇦Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018 Jun 7;16(8),1656-64.https://doi.org/10.1111/jth.14192

18. Özgür G, Beyan C. Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. Transfusion and Apheresis Science. 2018 02;57(1):13- 15. https://doi.org/10.1016/j.transci.2018.02.008

19. Rodríguez-Pintó I, Lozano M, Espinosa G, Cervera R. Plasma exchange in catastrophic antiphospholipid syndrome. Presse Med. 2019 Nov 4. pii: S0755-4982(19)30462-2.

20. Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019 Aug;19(3):281-8. https://doi.org/10.1007/s10238-019-00565-8

21. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb; 7(1):26-30. https://doi.org/10.1177/1759720X14554793